AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6159711
Drug: 4-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 2 months followed by thiacetazone plus isoniazid for 8 months
Trial: 6159711
Drug: 4-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 1 month followed by thiacetazone plus isoniazid for 6 months
Trial: 6159711
Drug: 4-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 1 month followed by twice-weekly streptomycin, isoniazid and pyrazinamide for 6 months
Trial: 6159711
Drug: 4-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-drug regimen without pyrazinamide for 2 months followed by thiacetazone plus isoniazid for 6 months
Trial: 6140492
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg twice a day for seven days
Trial: 6140492
Drug: Single 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2 g dose of metronidazole after placebo failure
Trial: 6140492
Drug: Recurrence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recurrence of infection after treatment
Trial: 30045174
Drug: Overall breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall breast augmentation (both groups)
Trial: 26219549
Drug: Face Mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face Mask (FM) therapy with a force of 400g for each side
Trial: 26219549
Drug: Skeletal Anchorage
RxNorm normalized name: Spongia officinalis skeleton extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skeletal Anchorage (SA) therapy with intermaxillary elastics and a force of 200g
Trial: 24859491
Drug: Moclobemide (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (450 mg/day)
Trial: 20399994
Drug: Rosuvastatin 5
RxNorm normalized name: rosuvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5 mg (steady state)
Trial: 20399994
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg (steady state)
Trial: 20399994
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg (steady state)
Trial: 9135508
Drug: Idarubicin 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin 35 mg/m2 day 1 and prednimustine 100 mg/m2 days 2-6, every 21 days
Trial: 9135508
Drug: Idarubicin 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin 15 mg/m2 days 1, 2 and 3 and prednimustine 100 mg/m2 days 2-6, every 21 days
Trial: 7534946
Drug: Saruplase (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saruplase (20 mg bolus plus 60 mg continuous 1 h i.v. infusion)
Trial: 3556262
Drug: Compound analgesic/anti-emetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound analgesic/anti-emetic formulation (paracetamol 500 mg, codeine phosphate 8 mg, buclizine hydrochloride 6.25 mg, dioctyl sodium sulphosuccinate 10 mg) taken as two tablets during acute attack
Trial: 29857919
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of rosuvastatin (5, 10, and 20 mg) with ezetimibe (10 mg)
Trial: 29857919
Drug: Rosuvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin monotherapy (5, 10, and 20 mg)
Trial: 26709942
Drug: Modified-live virus
RxNorm normalized name: Measles virus vaccine live attenuated
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-live virus vaccines (groups B, C, D, E)
Trial: 22867111
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (50,000 IU compounded vitamin D3 capsule monthly)
Trial: 22867111
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical inert capsule)
Trial: 17574729
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER (2mg once daily) for 12 months
Trial: 8076917
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg acetylsalicylic acid/day
Trial: 2692264
Drug: Metronidazole and
RxNorm normalized name: metronidazole and diloxanide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole and ampicillin treatment for one to four days, wounds closed on the fourth day.
Trial: 30898323
Drug: Individual female-specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual female-specific cognitive behavioral therapy (I-FS-CBT)
Trial: 30898323
Drug: Group female-specific
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group female-specific cognitive behavioral therapy (G-FS-CBT)
Trial: 26912161
Drug: α-linolenic acid
RxNorm normalized name: α-linolenic acid
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-linolenic acid (ALA) treatment (4.0 g daily for 12 weeks)
Trial: 22151299
Drug: Training administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training administered to working mothers on breastfeeding techniques, duration: five home visits starting two weeks before returning to work until infants are six months old.
Trial: 17649720
Drug: ATRA +
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA + As4S4 + chemotherapy
Trial: 14997024
Drug: Standard parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parenteral nutrition protocols
Trial: 7868711
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg itraconazole twice daily
Trial: 7868711
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day itraconazole
Trial: 31128221
Drug: Stratified approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified approach using post-trial data from participants taking the drug after trial
Trial: 27436028
Drug: Particulate steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Particulate steroids
Trial: 27436028
Drug: Non-particulate steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-particulate steroids
Trial: 25811109
Drug: L-glutamine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamine (25 g)
Trial: 25811109
Drug: Whole protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole protein (25 g)
Trial: 24014905
Drug: Primaquine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (15 mg single oral dose)
Trial: 15153172
Drug: Lumiracoxib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 800 mg once daily
Trial: 9791684
Drug: Remantadine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remantadine (1.5 mg/kg body weight 3 times a day for 3 days)
Trial: 9791684
Drug: Arbidole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbidole (10 mg/kg body weight in 4 portions for 5 days)
Trial: 1619184
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (Mg oxide) to bring Mg intake to 8 mg/kg body weight/day
Trial: 6442713
Drug: 1000 ml
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 ml of 10% Intralipid added to TPN over a period of 12 h (1.8‐2.1 g/kg/day)
Trial: 29382803
Drug: Mechanical Thrombectomy
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical Thrombectomy After Intravenous Alteplase
Trial: 25204642
Drug: Ultrafine carbon
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrafine carbon particles (64 μg/m³; 6.1 ± 0.4 × 10⁵ particles/cm³ for 2 h)
Trial: 19578132
Drug: Supervised diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised diet and exercise plus transdermal testosterone (50 mg once daily)
Trial: 19578132
Drug: Supervised diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised diet and exercise plus transdermal testosterone
Trial: 17538804
Drug: Metronidazole 0.75%
RxNorm normalized name: METRONIDAZOLE 0.75% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 0.75% gel applied twice daily for at least 15 days
Trial: 15045047
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg azithromycin daily (high dose)
Trial: 15045047
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg azithromycin twice weekly (low dose)
Trial: 15045047
Drug: Both high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both high and low dose azithromycin
Trial: 9889712
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride baths (30 and 50 g/l)
Trial: 9889712
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride baths (50 g/l)
Trial: 7701577
Drug: OKT3 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 (5 mg/d)
Trial: 7701577
Drug: ATG-F (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG-F (4 mg/kg/d)
Trial: 2707058
Drug: Aerosolized metaproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized metaproterenol delivered by metered‐dose inhaler (MDI) with a spacer device (Aerochamber)
Trial: 28378366
Drug: Low patient-centered
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low patient-centered communication (L-PCC) style
Trial: 16980741
Drug: Antioxidant agent
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant agent administered into dental tissues after endo bleaching, cavity filled immediately.
Trial: 9284858
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day citalopram alone
Trial: 9284858
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day citalopram with brief psychosocial intervention
Trial: 7890822
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.3-0.6 mg/kg/day
Trial: 30825414
Drug: Participatory intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participatory intervention using an online social network with weekly posters and active communication with mothers.
Trial: 29198191
Drug: Culturally appropriate
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally appropriate multi-faceted oral health promotion intervention including anticipatory guidance, Motivational Interviewing, health and dental care for mothers during pregnancy and children at 6, 12, and 18 months.
Trial: 19811918
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide only (C)
Trial: 16968397
Drug: IVIg therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg therapy (2 g/kg body weight, monthly for 6 months)
Trial: 15164224
Drug: Insulin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (two types) injected subcutaneously
Trial: 11001240
Drug: Imipramine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine at a fixed, targeted, weight‐adjusted dose of 2.25 mg x kg(‐1) x day(‐1)
Trial: 8322488
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms dose of influenza vaccine
Trial: 8322488
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms dose of influenza vaccine
Trial: 8322488
Drug: 60 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 micrograms dose of influenza vaccine
Trial: 3964359
Drug: Silver sulfadiazene
RxNorm normalized name: SILVER SULFADIAZINE 10 g in 1000 g TOPICAL CREAM [Silver Sulfadiazene]
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver sulfadiazene cream (Silvadene)
Trial: 27834743
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment arm
Trial: 24605793
Drug: Perampanel 12
RxNorm normalized name: perampanel 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 12 mg during the extension blinded Conversion Period (n=217)
Trial: 24605793
Drug: Perampanel 12
RxNorm normalized name: perampanel 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 12 mg during weeks 1-13 of the extension Maintenance Period (n=181)
Trial: 24605793
Drug: Perampanel 12
RxNorm normalized name: perampanel 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 12 mg during the extension
Trial: 22672363
Drug: Diet high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet high in fibre (>25 g/day)
Trial: 22672363
Drug: Diet low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet low in fibre (<25 g/day)
Trial: 22672363
Drug: Diet low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet low in fibre (g/day)
Trial: 22672363
Drug: Diet low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet low in carbohydrate (g/day)
Trial: 18327813
Drug: Aprepitant 125
RxNorm normalized name: aprepitant 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125 mg orally on Day 1 followed by 80 mg on Days 2-3 (Arm A)
Trial: 18327813
Drug: Aprepitant 125
RxNorm normalized name: aprepitant 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125 mg orally on Day 1 and placebo on Days 2-3 (Arm B)
Trial: 6173522
Drug: Captopril 32.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 32.5 mg/day
Trial: 6173522
Drug: Captopril 75
RxNorm normalized name: captopril 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 75 mg/day
Trial: 12200983
Drug: Albendazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (15 mg/kg/day) for 28 days
Trial: 26547425
Drug: GXR all-active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GXR all-active (1-4 mg/day)
Trial: 26547425
Drug: GXR am
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GXR am (1-4 mg/day in the morning)
Trial: 26547425
Drug: GXR pm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GXR pm (1-4 mg/day in the evening)
Trial: 23627550
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care including multiple point‐of‐care interventions (e.g., standing orders, EHR reminders), performance measurement, and financial incentives.
Trial: 21565135
Drug: Suoquan Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suoquan Pill (SQP) 10 g per oral dose twice daily for 8 weeks
Trial: 21565135
Drug: Wuling Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuling Powder (WLP) 10 g per oral dose twice daily for 8 weeks
Trial: 21565135
Drug: Placebo powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder 10 g per oral dose twice daily for 8 weeks
Trial: 21565135
Drug: Suoquan Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suoquan Pill (SQP) and Wuling Powder (WLP)
Trial: 19276670
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy consisting of 2‐3 cycles of cisplatin and 5‐Fluorouracil followed by low dose weekly cisplatin based chemoradiotherapy (treatment arm: n = 48)
Trial: 17888186
Drug: 400 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mL/day of red wine for two weeks
Trial: 11322056
Drug: 0.5% Apraclonidin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% Apraclonidin eye drops applied twice daily for 8 days
Trial: 11322056
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication (0.9% NaCI) applied according to the same protocol
Trial: 9063761
Drug: 19.3% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19.3% glucose polymer solution (C trial)
Trial: 9063761
Drug: 6.9% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.9% glucose polymer solution (D trial)
Trial: 26277295
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of intracoronary diltiazem
Trial: 16840514
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) intravenous infusion at 125 mg kg(‐1) h(‐1) for 15 min, then 25 mg kg(‐1) h(‐1) for 20 min prior to and throughout exercise
Trial: 10959784
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment with quadrant root planing)
Trial: 8638837
Drug: Ropivacaine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 20 mg/h
Trial: 8638837
Drug: Ropivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 10 mg/h
Trial: 1350610
Drug: Allopurinol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (50 mg four times a day)
Trial: 1350610
Drug: Dimethyl sulfoxide
RxNorm normalized name: Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dimethyl sulfoxide (500 mg four times a day)
Trial: 1350610
Drug: Sulfasalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (2 gm daily) alone
Trial: 31402562
Drug: Bevacizumab (Bev)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (Bev) in combination with sequential chemotherapy
Trial: 28971905
Drug: 6‐methylprednisolone 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐methylprednisolone 1 mg/kg/day
Trial: 12796664
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor exercises (PFE) with biofeedback and physical therapist guidance, performed before and after surgery, with home exercises twice daily after surgery.
Trial: 1450186
Drug: Remoxipride (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (30 to 90 mg)
Trial: 1450186
Drug: Remoxipride (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (120 to 240 mg)
Trial: 1450186
Drug: Remoxipride (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (300 to 600 mg)
Trial: 1450186
Drug: Haloperidol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (15 to 45 mg)
Trial: 29260507
Drug: Daratumumab in
RxNorm normalized name: daratumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab in combination with bortezomib and dexamethasone (DVd)
Trial: 12009297
Drug: Polysaccharide Nm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide Nm vaccine
Trial: 2287557
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of pentoxifylline and theophylline
Trial: 2287557
Drug: Theophylline administration
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline administration alone
Trial: 31825075
Drug: High-carbohydrate beverage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate beverage (CHO; 210 kcal; 0 g fat/56 g carbohydrates/0 g protein)
Trial: 31229045
Drug: Everolimus with
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus with reduced-concentration tacrolimus and steroids
Trial: 31229045
Drug: Mycophenolate, tacrolimus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycophenolate, tacrolimus, and steroids
Trial: 23688534
Drug: Luteolin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteolin and quercetin dietary supplement (100 mg luteolin, 70 mg quercetin, 30 mg rutin per capsule, 1 capsule per 10 kg weight per day with food)
Trial: 23688534
Drug: Luteolin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteolin and quercetin dietary supplement